ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
First-line therapy with trastuzumab and vinorelbine achieves high response rates in HER2-overexpressing metastatic breast cancer,
Inpharma Weekly
◽
10.2165/00128413-200816500-00058
◽
2008
◽
Vol &NA;
(1650)
◽
pp. 17
Author(s):
&NA;
Keyword(s):
Breast Cancer
◽
Metastatic Breast Cancer
◽
Metastatic Breast
◽
Response Rates
◽
High Response
◽
First Line
◽
First Line Therapy
◽
Line Therapy
Download Full-text
Related Documents
Cited By
References
WITHDRAWN: Combined epirubicin and vinorelbine as first-line therapy in metastatic breast cancer: a pilot study performed by the Danish Breast Cancer Cooperative Group
The Breast
◽
10.1054/brst.2002.0469
◽
2002
◽
Author(s):
B. Ejlertsen
◽
I. Højris
◽
S. Hansen
◽
K. Møholt
◽
B. Kristensen
◽
...
Keyword(s):
Breast Cancer
◽
Metastatic Breast Cancer
◽
Pilot Study
◽
Metastatic Breast
◽
Cooperative Group
◽
First Line
◽
First Line Therapy
◽
Line Therapy
Download Full-text
Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial
British Journal of Cancer
◽
10.1038/sj.bjc.6603351
◽
2006
◽
Vol 95
(7)
◽
pp. 788-793
◽
Cited By ~ 43
Author(s):
A Chan
◽
◽
M Martin
◽
M Untch
◽
M G Gil
◽
...
Keyword(s):
Breast Cancer
◽
Metastatic Breast Cancer
◽
Cancer Patients
◽
Phase Ii Trial
◽
Metastatic Breast
◽
Breast Cancer Patients
◽
First Line
◽
First Line Therapy
◽
Line Therapy
◽
Her 2
Download Full-text
Phase II Trial of Weekly Vinorelbine and Trastuzumab as First‐Line Therapy in Patients with HER2 + Metastatic Breast Cancer
The Oncologist
◽
10.1634/theoncologist.7-5-410
◽
2002
◽
Vol 7
(5)
◽
pp. 410-417
◽
Cited By ~ 107
Author(s):
Mohammad Jahanzeb
◽
Joanne E. Mortimer
◽
Furhan Yunus
◽
David H. Irwin
◽
James Speyer
◽
...
Keyword(s):
Breast Cancer
◽
Metastatic Breast Cancer
◽
Phase Ii
◽
Phase Ii Trial
◽
Metastatic Breast
◽
First Line
◽
First Line Therapy
◽
Line Therapy
Download Full-text
Final results from PERUSE, a global study of pertuzumab (P), trastuzumab (H) and investigator’s chosen taxane as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)
10.1055/s-0041-1730221
◽
2021
◽
Author(s):
A Schneeweiss
◽
D Miles
◽
E Ciruelos
◽
F Puglisi
◽
T Peretz-Yablonski
◽
...
Keyword(s):
Breast Cancer
◽
Metastatic Breast Cancer
◽
Metastatic Breast
◽
First Line
◽
Her2 Positive
◽
First Line Therapy
◽
Line Therapy
◽
Global Study
◽
Locally Recurrent
Download Full-text
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan
Anti-Cancer Drugs
◽
10.1097/cad.0b013e328302eb15
◽
2008
◽
Vol 19
(7)
◽
pp. 753-759
◽
Cited By ~ 8
Author(s):
Nahomi Tokudome
◽
Yoshinori Ito
◽
Kiyohiko Hatake
◽
Masakazu Toi
◽
Muneaki Sano
◽
...
Keyword(s):
Breast Cancer
◽
Metastatic Breast Cancer
◽
Phase Ii
◽
Pharmacokinetic Study
◽
Metastatic Breast
◽
First Line
◽
First Line Therapy
◽
Multicenter Phase
◽
Line Therapy
Download Full-text
A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib (SOR) in Combination with Paclitaxel (PAC) as a First-Line Therapy in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (BC).
10.1158/0008-5472.sabcs-09-44
◽
2009
◽
Cited By ~ 23
Author(s):
W. Gradishar
◽
V. Kaklamani
◽
T. Prasad Sahoo
◽
D. Lokanatha
◽
V. Raina
◽
...
Keyword(s):
Breast Cancer
◽
Metastatic Breast Cancer
◽
Metastatic Breast
◽
Efficacy And Safety
◽
First Line
◽
Double Blind
◽
First Line Therapy
◽
Line Therapy
◽
Locally Recurrent
Download Full-text
Superiority of Docetaxel + Capecitabine Compared to Docetaxel + Epirubicin as First-Line Therapy for Metastatic Breast Cancer – Final Results of the ERASME-4 Study.
10.1158/0008-5472.sabcs-09-2099
◽
2009
◽
Author(s):
T. Bachelot
◽
A. Bajard
◽
I. Ray-Coquard
◽
J. Provencal
◽
D. Coeffic
◽
...
Keyword(s):
Breast Cancer
◽
Metastatic Breast Cancer
◽
Metastatic Breast
◽
First Line
◽
First Line Therapy
◽
Line Therapy
Download Full-text
Abstract P3-14-24: Overall Survival Benefit Observed with Lapatinib (L) Plus Paclitaxel (P) as First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer (MBC)
10.1158/0008-5472.sabcs10-p3-14-24
◽
2010
◽
Cited By ~ 4
Author(s):
Z-z Guan
◽
B-h Xu
◽
W Arpornwirat
◽
Z-s Tong
◽
V Lorvidhaya
◽
...
Keyword(s):
Breast Cancer
◽
Overall Survival
◽
Metastatic Breast Cancer
◽
Survival Benefit
◽
Metastatic Breast
◽
First Line
◽
First Line Therapy
◽
Line Therapy
◽
Overall Survival Benefit
Download Full-text
Abstract P3-02-11: First Analysis of the Value of Circulating Epithelial Tumor Cells and Circulating Endothelial Cells (CTCs/CECs) in Patients with HER-2 Negative Recurrent or Metastatic Breast Cancer Treated with Bevacizumab in Combination with Paclitaxel and Gemcitabine as First Line Therapy (AVALUZ Trial)
10.1158/0008-5472.sabcs10-p3-02-11
◽
2010
◽
Author(s):
L Manso
◽
E Ciruelos
◽
M Codes de Villena
◽
J de la Haba
◽
A Galán
◽
...
Keyword(s):
Breast Cancer
◽
Endothelial Cells
◽
Metastatic Breast Cancer
◽
Metastatic Breast
◽
Circulating Endothelial Cells
◽
First Line
◽
Epithelial Tumor
◽
First Line Therapy
◽
Line Therapy
◽
Her 2
Download Full-text
P1-14-01: Randomized Phase II Trial of Weekly vs. q 2-Weekly vs. q 3-Weekly Nanoparticle Albumin-Bound Paclitaxel with Bevacizumab as First-Line Therapy for Metastatic Breast Cancer.
10.1158/0008-5472.sabcs11-p1-14-01
◽
2011
◽
Author(s):
AD Seidman
◽
AK Conlin
◽
A Bach
◽
A Forero-Torres
◽
G Wright
◽
...
Keyword(s):
Breast Cancer
◽
Metastatic Breast Cancer
◽
Phase Ii
◽
Phase Ii Trial
◽
Metastatic Breast
◽
First Line
◽
First Line Therapy
◽
Line Therapy
◽
Randomized Phase Ii
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close